Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals) on September 9, 2019. The registrant is a Delaware corporation listed on the Nasdaq Capital Market under the symbol EYEG. The filing serves as a Regulation FD disclosure to furnish an updated investor presentation (Exhibit 99.1) intended for use at the H.C. Wainwright 21st Annual Global Investment Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a presentation deck and does not contain audited financial statements or a summary of financial results.
Material Changes
No material changes to financial performance or operations are reported in this specific filing. The document solely announces the availability of an updated investor presentation for an upcoming conference.
Guidance, Outlook, and Management Commentary
- Management Activity: Stephen From, President and CEO, is scheduled to present at the H.C. Wainwright conference on September 9, 2019, at approximately 4:40 p.m. Eastern Time.
- Forward-Looking Statements: The filing explicitly states that the information furnished, including the attached presentation, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The Company does not assume an obligation to update the information in the future.
- Emerging Growth Company: The registrant has elected to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the company name is EyeGate Pharmaceuticals, Inc. (EYEG), as the input metadata incorrectly referenced Kiora Pharmaceuticals.
- Review Exhibit 99.1 (the attached investor presentation) for actual financial data, pipeline updates, and strategic outlook, as this 8-K only references the exhibit.
- Confirm the date and time of the management presentation at the H.C. Wainwright conference if seeking real-time commentary.
- Note that the information in this filing is not incorporated by reference into other SEC filings unless specifically stated by the Company.